Reason for request

Inclusion on the list of medicines approved for hospital use.


Clinical Benefit


The actual benefit is substantial.

Clinical Added Value


In view of the results obtained in a population with an unfavourable prognosis and the size of the effect observed, the Transparency Committee considers that TORISEL provides a substantial improvement in actual benefit (IAB level II) compared with interferon alpha (ROFERON-A) in advanced renal cell carcinoma patients with at least 3 of the 6 prognostic risk factors.

Contact Us

Évaluation des médicaments